Although in the present study gliomas were classified accordingly to the currently used 2016 WHO classification of the brain tumors, it is desirable in the future to molecularly characterize diffuse astrocytic gliomas, IDH-wildtype, in order to recognize those that can indeed be classified as diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV [31,32]. This evidence concerns the gene IDH2 and brain neoplasm.